Age-associated defect in ADCC response to COVID-19 vaccine
- PMID: 40593808
- PMCID: PMC12217920
- DOI: 10.1038/s41541-025-01196-9
Age-associated defect in ADCC response to COVID-19 vaccine
Abstract
We investigated age-associated effects of SARS-CoV-2 vaccination in elderly individuals (n = 50, mean age 79) after six SARS-CoV-2 vaccine doses. While neutralization titers remained comparable across age groups, Fc-mediated effector functions declined with age. Individuals >80 demonstrated reduced antibody-dependent cellular cytotoxicity (ADCC), via a surrogate ADCC-signaling assay, correlating with diminished IgG1 binding. These findings highlight age-related impairments in Fc-mediated responses, with implications for immune protection and vaccine strategies in older populations.
© 2025. The Author(s).
Conflict of interest statement
Competing interests: The authors declare no competing interests.
Figures
References
-
- Romero-Olmedo, A. J. et al. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults. Nat. Microbiol.7, 195–199 (2022). - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
